Literature DB >> 11446475

Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.

R Halperin1, S Zehavi, L Habler, E Hadas, I Bukovsky, D Schneider.   

Abstract

OBJECTIVE: The aim of this study was to determine whether immunohistochemical analysis of molecular parameters can provide an alternative method for classification of endometrial cancer cases according to their aggressiveness.
METHODS: Sixty-four cases of endometrial carcinoma were assigned to three groups: group I--28 cases of endometrioid well and moderately differentiated (G1-G2) carcinoma; group II--14 cases of endometrioid poorly differentiated (G3) carcinoma; group III--22 cases of serous papillary endometrial cancer. Immunohistochemistry was used to determine the existence of estrogen receptors (ER), progesterone receptors (PR), and the expression of bcl-2, p53, HER-2/neu and Ki-67.
RESULTS: There was a significant difference in the immunohistochemical profile of the studied molecular parameters comparing the three study groups. The endometrioid G1-G2 cases (group I) were characterized by increased immunoreactivity for ER and PR (85.7% and 78.6%, respectively), increased immunoreactivity for bcl-2 (42.8%) and low expression of p53 (14.3%) and HER-2/neu (14.3%). In contrast to group I cases, the serous papillary endometrial cancer cases (group III) were characterized by immunonegativity for ER, PR and bcl-2 and high immunoreactivity for p53 (81.8%) and HER-2/neu (45.4%). The endometrioid G3 cases (group II) demonstrated an intermediate immunoprofile, characterized by immunonegativity for ER, PR and HER-2/neu, low immunoreactivity for bcl-2 (7.1%) and high expression of p53 (57.1%). The expression of Ki-67 did not differ significantly comparing the different cases of endometrial cancer.
CONCLUSION: This study provides evidence that the immunohistochemical analysis of endometrial carcinoma differentiates between different grades and histological types, thus being useful in the distinction of high risk cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11446475

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  20 in total

Review 1.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 2.  Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.

Authors:  Laura Cerezo; Higinia Cárdenes; Helen Michael
Journal:  Clin Transl Oncol       Date:  2006-04       Impact factor: 3.405

3.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

4.  Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray.

Authors:  A Alkushi; J Irving; F Hsu; B Dupuis; C L Liu; M Rijn; C B Gilks
Journal:  Virchows Arch       Date:  2003-02-12       Impact factor: 4.064

5.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

6.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

Review 7.  Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.

Authors:  Sigurd F Lax
Journal:  Virchows Arch       Date:  2004-01-28       Impact factor: 4.064

8.  Molecular biology of gynecological cancer.

Authors:  Kenzo Sonoda
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

9.  Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma.

Authors:  Richard Colling; Tito Lopes; Nagiindra Das; Joe Mathew
Journal:  BMJ Case Rep       Date:  2010-11-05

10.  DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium.

Authors:  Manohar Pradhan; Ben Davidson; Vera Maria Abeler; Håvard Emil Danielsen; Claes Göran Tropé; Gunnar Balle Kristensen; Björn Åke Risberg
Journal:  Virchows Arch       Date:  2012-07-24       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.